BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $7.49M; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value (m); Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $7.49M | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $7.49M |
| Deferred revenue · latest quarter (USD) | (m) | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due within 1 year (USD) | (m) | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due after 1 year (USD) | (m) | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | 12.38M USD | Liabilities |
| Borrowing debt | (m) | |
| Amounts owed to suppliers | 7.49M USD | Accounts Payable, Current |
| Total deferred revenue | (m) | |
| Deferred revenue due within one year | (m) | |
| Deferred revenue due after one year | (m) | |
| Reported other obligations due within one year | (m) | Other Liabilities, Current |
| Reported other noncurrent obligations | (m) | |
| Deferred revenue included in other noncurrent obligations | (m) |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- (m)
- Other obligations · due after 1 year (USD)
- (m)
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Obligation categories | (m) |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $7.49M | (m) | (m) | (m) | $12.38M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $7.32M | (m) | (m) | (m) | $11.76M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $7.07M | (m) | (m) | (m) | $11.01M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $6.42M | (m) | (m) | (m) | $9.07M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $6.00M | (m) | (m) | (m) | $8.62M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $6.80M | (m) | (m) | (m) | $11.03M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $6.08M | (m) | $300.00K | (m) | $9.60M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $4.60M | (m) | (m) | (m) | $8.08M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $5.34M | (m) | (m) | (m) | $9.21M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $4.69M | (m) | (m) | (m) | $8.90M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $4.95M | (m) | (m) | (m) | $9.07M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $3.93M | (m) | (m) | (m) | $8.26M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $5.19M | (m) | (m) | (m) | $9.63M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $7.80M | (m) | (m) | (m) | $12.71M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $6.22M | (m) | (m) | (m) | $11.47M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $6.39M | (m) | (m) | (m) | $11.87M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $5.29M | (m) | (m) | (m) | $11.11M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $4.57M | (m) | (m) | (m) | $11.30M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $3.70M | (m) | (m) | (m) | $9.94M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $2.74M | (m) | (m) | (m) | $9.61M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $3.00M | (m) | (m) | (m) | $12.06M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $2.55M | (m) | (m) | (m) | $12.37M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $5.42M | (m) | (m) | (m) | $15.79M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $3.28M | (m) | (m) | (m) | $6.71M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $4.60M | (m) | (m) | (m) | $9.40M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $4.57M | (m) | (m) | (m) | $9.06M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $14.68M | (m) | (m) | (m) | $18.76M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $9.14M | (m) | (m) | (m) | $14.59M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $8.77M | (m) | (m) | (m) | $13.38M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $5.03M | (m) | (m) | (m) | $11.53M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $4.55M | (m) | (m) | (m) | $6.21M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $2.60M | (m) | (m) | (m) | $3.79M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $4.18M | (m) | (m) | (m) | $8.15M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $3.26M | (m) | (m) | (m) | $5.58M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $1.42M | (m) | (m) | (m) | $5.54M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $275.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $227.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $362.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $345.00K | (m) | (m) | (m) | $864.00K | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $352.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $355.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $281.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $1.17M | (m) | (m) | (m) | $2.95M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $335.00K | (m) | (m) | (m) | $2.84M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $755.00K | (m) | (m) | (m) | $2.53M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $922.00K | (m) | (m) | (m) | $2.73M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $1.54M | (m) | (m) | (m) | $3.24M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | $1.30M | (m) | (m) | (m) | $2.50M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $757.00K | (m) | (m) | (m) | $1.92M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $326.00K | (m) | (m) | (m) | $3.33M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $228.00K | (m) | (m) | (m) | $1.99M | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | $446.00K | (m) | (m) | (m) | $1.68M | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $373.00K | (m) | (m) | (m) | $1.44M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $246.00K | (m) | (m) | (m) | $1.27M | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $358.00K | (m) | (m) | (m) | $1.33M | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $194.00K | (m) | (m) | (m) | $1.26M | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $515.00K | (m) | (m) | (m) | $1.60M | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $325.00K | (m) | (m) | (m) | $1.43M | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $244.00K | (m) | (m) | (m) | $1.26M | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | $159.00K | (m) | (m) | (m) | $909.00K | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | $296.00K | (m) | (m) | (m) | $1.37M | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $307.00K | (m) | (m) | (m) | $1.55M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |